Description
GSK-2636771isaninhibitorofthep110βisoformofPI3K.GSK-2636771displaysanticancerchemotherapeuticactivityinPTEN-deficientcancerssuchasglioblastomas,prostatecancers,andendometrialcancers.Thiscompoundiscurrentlyinclinicaltrials.
GSK-2636771isaninhibitorofthep110βisoformofPI3K.GSK-2636771displaysanticancerchemotherapeuticactivityinPTEN-deficientcancerssuchasglioblastomas,prostatecancers,andendometrialcancers.Thiscompoundiscurrentlyinclinicaltrials.
CasNo. | 1372540-25-4 |
---|---|
Purity | ≥98.5% |
Formula | C22H22F3N3O3 |
FormulaWt. | 433.42 |
IUPACName | 2-methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-morpholin-4-ylbenzimidazole-4-carboxylicacid |
Solubility | SolubleinDMSO,andwaterwith1eq.ofbase |
Appearance | WhitePowder |
StoreTemp | -20°C |
---|---|
ShipTemp | Ambient |
InfoSheet | G7346InfoSheetPDF |
---|---|
Brochures | PI3K-Akt-mTORCPathwayBooklet |
WeigeltB,WarnePH,LambrosMB,etal.PI3KPathwayDependenciesinEndometrioidEndometrialCancerCellLines.ClinCancerRes.2013Jul1;19(13):3533-44.PMID:23674493.